DePuy Synthes purchases OrthoSpin and its robotic external fixation system

Johnson & Johnsons (NYSE: JNJ) DePuy Synthes – through its subsidiary Synthes GmbH – today announced the acquisition of OrthoSpin.

OrthoSpin, based in Israel, is developing a robotic external fixation system for orthopedic treatments. The platform is used in conjunction with the multi-axial correction system Maxframe from DePuy Synthes, an external ring fixation system.

OrthoSpin received FDA approval for its second-generation, robotic, digital-enabled external fixation system G2 in January of this year.

According to a press release, the acquisition underscores J & J’s efforts to drive innovation in medical technology, with the company keeping an eye on OrthoSpin over the years. OrthoSpin raised $ 3 million for the external fixation system in a Series A funding round led by J&J in July 2018. The company also led the OrthoSpin Series B in March 2020.

DePuy Synthes launched its Maxframe system in 2017 and recently launched new frame innovations and planned next-generation software. Company officials believe that the acquisition of OrthoSpin will position DePuy in a better position to support healthcare professionals and patients during the complex post-operative recovery phase.

Upon completion of the acquisition, DePuy Synthes plans to integrate OrthoSpin and develop a supply chain before making the product generally available in the “near future”. The financial terms of the acquisition were not disclosed.

“DePuy Synthes is committed to helping patients in need of surgery to correct deformities,” said Oray Boston, Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, in the press release. “The acquisition of OrthoSpin clearly demonstrates our strong desire to help these patients navigate their recovery with more confidence and less uncertainty in adjusting braces.

“It also demonstrates our commitment to bringing transformative advances in medical technology to the industry through the application of automated technologies that address a wide variety of orthopedic challenges.”

J&J announced FDA approval and the launch of its robotic knee replacement system, Velys, in the United States earlier this year.

Comments are closed.